8840 WILSHIRE BLVD, BEVERLY HILLS, CA
Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA
Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Other Events, Press Release
Material disclosure
Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Shareholder votes
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Q2
Q1
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload